Improving evidence based care for locally advanced prostate cancer.
Not Applicable
Completed
- Conditions
- Effectiveness of clinical networks as change agents in clinical practice.Increase appropriate utilisation of adjuvant radiotherapy for men with locally advanced prostate cancer.Public Health - Health promotion/educationCancer - Prostate
- Registration Number
- ACTRN12611001251910
- Lead Sponsor
- The Sax Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Male
- Target Recruitment
- 900
Inclusion Criteria
1) Urology clinicians and multidisciplinary teams within the 9 hospitals with representation in the NSW Agency for Clinical Innovation Urology clinical network.
2) High-risk patients with locally advanced prostate cancer following radical prostatectomy.
Exclusion Criteria
None
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Referral to radiotherapy. This outcome will be assessed through medical audit of hospital records.[Baseline, 6 months post-intervention and end of study 18 months post-intervention commencement.];Uptake of radiotherapy or enrolment into the RAVES trial (ACTRN12611000781943). This outcome will be assessed through medical audit of hospital records.[Baseline, 6 months post-intervention and end of study 18 months post-intervention commencement.];Time between surgery and radiotherapy. This outcome will be assessed through medical audit of hospital records.[Baseline, 6 months post-intervention and end of study 18 months post-intervention commencement.]
- Secondary Outcome Measures
Name Time Method Clinicians' knowledge and attitudes. This outcome will be assessed through pen and paper surveys. The measures using Likert scales will be developed through pilot testing their feasibility and reliability.[Baseline, 6 months post-intervention and end of study 18 months post-intervention commencement.]
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does clinical network implementation (ACTRN12611001251910) improve adherence to adjuvant radiotherapy guidelines for locally advanced prostate cancer?
What are the key biomarkers for selecting prostate cancer patients who benefit most from adjuvant radiotherapy in ACTRN12611001251910 clinical network trials?
What adverse events are associated with adjuvant radiotherapy in locally advanced prostate cancer and how does ACTRN12611001251910 address their management?
How does ACTRN12611001251910 compare to other guideline implementation strategies in enhancing prostate cancer treatment outcomes?
What molecular pathways or drug classes are targeted by adjuvant radiotherapy optimization in ACTRN12611001251910 for locally advanced prostate cancer?